ProCE Banner Activity

Reflections on Optimizing Biomarker Testing for Colorectal Cancer in the Era of Immunotherapy

Clinical Thought
Using MSI and MMR testing to inform treatment decisions with immune checkpoint inhibitors is improving outcomes in colorectal cancer, but many questions remain. Read our thoughts on how these tools are improving clinical practice.

Released: April 25, 2017

Expiration: April 24, 2018

No longer available for credit.

Share

Faculty

Robert A. Anders

Robert A. Anders, MD, PhD

Associate Professor
Department of Pathology
Johns Hopkins School of Medicine
Staff Physician
Department of Pathology
Johns Hopkins Hospital
Baltimore, Maryland

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Robert A. Anders, MD, PhD

Associate Professor
Department of Pathology
Johns Hopkins School of Medicine
Staff Physician
Department of Pathology
Johns Hopkins Hospital
Baltimore, Maryland

Robert A. Anders, MD, PhD, has disclosed that he has received a salary from Stand Up to Cancer, consulting fees from Adaptive Biotech, and funds for research support from 5-Prime Therapeutics, Bristol-Myers Squibb, and Merck.